tiprankstipranks

Bellus Health reports Q3 EPS (20c), consensus (17c)

"We are pleased to announce the initiation of our CALM Phase 3 program, which we expect to be the final clinical step in potentially bringing BLU-5937, our P2X3 antagonist product candidate, to patients burdened by RCC, if approved. To add, this quarter, we have also made key advancements to ensure successful execution of these pivotal trials, including communicating with regulatory officials, conducting validation work on the VitaloJAK – as well as strengthening our cash position," commented Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "With no approved treatments in the United States, RCC remains a high unmet need and we are encouraged by BLU-5937’s potential to be an innovative and best-in-class product in the treatment landscape, if approved. We look forward to advancing the CALM program and expect to share topline data from CALM-1 in the second half of 2024."

Confident Investing Starts Here:

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue